BGI’s hereditary risk screening cancer panels target genes previously linked to a predisposition of cancer. Panel selection was based on expert curation of scientific literature and other high quality resources, including formal medical guidelines.
BGI’s Hereditary Breast and Ovarian (HBOC) panel provides health providers and patients with information on 21 genes associated with Hereditary Breast and Ovarian Cancer (HBOC) based on recent scientific and clinical literature. BGI detects different alterations including germline SNV, Indels and CNV.
Patients suspected of being at increased risk of HBOC
20 working days
Peripheral blood, DNA, Saliva
Target region capture, high-throughput sequencing
Sentis BRCA (2 genes) panel
Sentis Hereditary Breast and Ovarian (21 genes) panel
BRCA1, BRCA2, CHEK2, PALB2, BRIP1, TP53, PTEN, STK11, CDH1, ATM, BARD1, MLH1,NBN, MRE11A,MSH2, MSH6, MUTYH, PMS1,PMS2, RAD50, RAD51C
Counselling and consent
Sample shipped to BGI and analyzed
Report and Genetic counselling